Drug Discovery

AI Revolutionizes FGFR2/3 Cancer Therapy Design and Efficacy
Research & Development AI Revolutionizes FGFR2/3 Cancer Therapy Design and Efficacy

In the quest to combat cancer, innovation sits at the heart of every breakthrough. The relentless pursuit of effective therapies has led scientists on a path filled with challenges and triumphs. As many grapple with diseases like intrahepatic cholangiocarcinoma, breast and bladder cancers,

Can PPP2R1A Mutations Unlock New Hope for Ovarian Cancer?
Research & Development Can PPP2R1A Mutations Unlock New Hope for Ovarian Cancer?

Ivan Kairatov, a highly respected expert in the Biopharma industry, delves into the groundbreaking findings surrounding PPP2R1A mutations in ovarian clear cell carcinoma (OCCC) and their implications for cancer treatment. With his deep understanding of biotechnology and innovation, Kairatov shares

Will Kane Propel Uniquity Bio to Immunology Leadership?
Research & Development Will Kane Propel Uniquity Bio to Immunology Leadership?

In a groundbreaking move, Uniquity Bio has appointed industry veteran Will Kane as its new President and CEO amid its ambitious drive towards late-stage drug development. With over 30 years in the biopharmaceutical industry, Kane brings a wealth of experience from his previous executive roles at

Nanotech Drug Delivery Revolutionizes Modern Medicine
Tech & Innovation Nanotech Drug Delivery Revolutionizes Modern Medicine

Nanotechnology, already a powerful force in various industries, is now carving a defining role in medicine through advanced drug delivery systems. These systems employ nanoscale materials, unlocking unprecedented capabilities in targeting, efficiency, and personalization, marking a transformative

How Does the GAMP AI Guide Transform Pharma Compliance?
Biotech & Bioprocessing How Does the GAMP AI Guide Transform Pharma Compliance?

The pharmaceutical industry stands on the brink of a technological revolution with the recent release of the Good Automated Manufacturing Practice (GAMP) Artificial Intelligence Guide by the International Society for Pharmaceutical Engineering (ISPE). As pharmaceutical companies increasingly turn

FDA Approves Kerendia for Heart Failure with Moderate Ejection Fraction
Management & Regulatory FDA Approves Kerendia for Heart Failure with Moderate Ejection Fraction

In a significant development for cardiac care, Kerendia, a drug crafted by Bayer, has recently gained FDA approval to treat heart failure patients classified with moderate ejection fraction, defined as having a left ventricular ejection fraction (LVEF) of at least 40%. This approval potentially

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later